A biological herbicide approach using Xanthomonas translucens graminis (Xtg) to combat herbicide-resistant black-grass, a major arable weed. Offers potential as an inundative bioherbicide or as a source of synthetic bioactive molecules for weed management.
Black-grass is one of the most damaging arable weeds in the UK, with widespread herbicide resistance reducing the effectiveness of conventional chemical controls. This research investigates the use of a specific strain of Xanthomonas translucens graminis (Xtg) as a biological herbicide. The approach offers two potential pathways: direct application of Xtg as an inundative bioherbicide, or identification and synthesis of bioactive molecules produced during the infection process. The technology could provide farmers with a new tool for managing resistant weed populations while reducing reliance on traditional herbicides.
The research is at an early-to-mid stage of development. Initial laboratory and controlled-condition experiments have demonstrated lethal and non-lethal effects of Xtg on black-grass, including reductions in biomass and seed head production. Further validation is needed, including expanded screening across more black-grass populations, comprehensive crop safety testing on wheat, and small-plot field trials with and without conventional herbicide applications. The next phase will involve collaboration with an industry partner to determine whether to pursue Xtg as a formulated bioherbicide or to investigate bioactive molecule synthesis.
NIAB is an independent research organization headquartered in Cambridge, with sites across the UK, combining applied crop research with certification, advisory, and contract R&D for industry. Companies engage through co-located labs and glasshouses, a national network of replicated field trials, and a year-round demonstration farm for evaluation and private pilots. Service units provide seed and variety testing, quality assurance, and bespoke studies, while an industry-facing incubator and flexible pilot plots help move concepts to pre-commercial validation. Research is supported by competitive UK funding, including UKRI programs, alongside contract work, and a business development and IP team manages agreements, licensing, and trial confidentiality.